Compositions and Methods for Contraception in or Sterilization of Mammals

William Baumgartner, Elzer, Philip H., Enright, Frederick M.  |  2/23/2007 1:35:40 AM

Enright, Frederick M.; Jaynes, Jesse M.; Hansel, William; Melrose, Patricia A.; Elzer, Philip H.
Date Posted: 2/18/2004
Patent Status: issued
Patent Number: 6,680,058

Abstract:
Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to induce sterility or long-term contraception in mammals. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in mammals in vivo. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) The two components--the ligand and the lytic peptide--may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lytic peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lytic peptide.
Rate This Article:

Have a question or comment about the information on this page?

Innovate . Educate . Improve Lives

The LSU AgCenter and the LSU College of Agriculture

Top